Infections caused by non-tuberculous mycobacteria (NTM) are increasing globally and are
notoriously difficult to treat due to intrinsic resistance of these bacteria to many common …

Background Since the publication of the British Thoracic Society (BTS) Guideline on the
'Management of opportunistic mycobacterial infections' in 2000, our understanding of the …

Nontuberculous mycobacteria (NTM) are emerging human pathogens, causing a wide
range of clinical diseases affecting individuals who are immunocompromised and who have …

Seminal microbiological work of environmental nontuberculous mycobacteria (NTM)
includes the discovery that NTM inhabit water distribution systems and soil, and that the …

The effect of the clinical phenotype of Mycobacterium avium complex (MAC) lung disease on
treatment outcome and redevelopment of nontuberculous mycobacterial (NTM) lung disease …

Nontuberculous mycobacteria (NTM) are emerging pathogens that affect both
immunocompromised and immunocompetent patients. The development of molecular …

Little is known about the long-term natural history of Mycobacterium avium complex lung
disease (MAC-LD) in untreated patients with stable course. The aim of this study was to …

Background The advent of macrolides has led to therapeutic advances in the treatment of
Mycobacterium avium complex lung disease (MAC-LD). The aim of this study was to …

Limited data are available regarding the prognostic factors for patients with nontuberculous
mycobacterial pulmonary disease (NTM-PD). We investigated the prognostic factors …

The pathogen Mycobacterium avium complex (MAC) is the most common cause of
nontuberculous mycobacterial pulmonary disease worldwide. The decision to initiate long …